BIO Study On Follow-On Biologics Focuses On Trade-Off Between Savings And R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
Study extrapolates from CBO’s scoring of last year’s Senate bill to argue that “shorter exclusivity could lead to the worst of both worlds – fewer new biologics … and little savings.”
You may also be interested in...
Follow-On Biologics Would Increase Savings By 30 Percent With Coding Tweaks, CBO Says
Even without reimbursement changes, CBO estimates higher Medicare/Medicaid savings than in previous scoring of Senate bill.
Teva's Lucky Number Seven: Analysis Supports Shorter Exclusivity For Biologics
Paper by AEI fellow Brill challenges the assumptions in the 16-year estimate from Duke's Grabowski.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.